Progression of diabetes retinal status within community screening programmes and potential implications for screening intervals

Graham P. Leese, Irene M. Stratton, Martin Land, Max O. Bachmann, Colin Jones, Peter Scanlon , Helen C. Looker, Brian Ferguson

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)
12 Downloads (Pure)

Abstract

OBJECTIVE: This study aimed to follow the natural progression of retinal changes in patients with diabetes. Such information should inform decisions with regard to the screening intervals for such patients.

RESEARCH DESIGN AND METHODS: An observational study was undertaken linking the data from seven diabetes retinal screening programs across the U.K. for retinal grading results between 2005 and 2012. Patients with absent or background retinopathy were followed up for progression to the end points referable retinopathy and treatable retinopathy (proliferative retinopathy).

RESULTS: In total, 354,549 patients were observed for up to 4 years during which 16,196 patients progressed to referable retinopathy. Of patients with no retinopathy in either eye for two successive screening episodes at least 12 months apart, the conditions of between 0.3% (95% CI 0.3–0.8%) and 1.3% (1.0–1.6%) of patients progressed to referable retinopathy, and rates of treatable eye disease were <0.3% at 2 years. The corresponding progression rates for patients with bilateral background retinopathy in successive screening episodes were 13–29% and up to 4%, respectively, in the different programs.

CONCLUSIONS: It may be possible to stratify patients for risk, according to baseline retinal criteria, into groups with low and high risk of their conditions progressing to proliferative retinopathy. Screening intervals for such diverse groups of patients could safely be modified according to their risk.
Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalDiabetes Care
Volume38
Issue number3
Early online date18 Dec 2014
DOIs
Publication statusPublished - 1 Mar 2015

Cite this